Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUST: Ustekinumab With vs Without Methotrexate in Active Psoriatic Arthritis
2015-005777-20Phase 3Completed
- Sponsor
- Fraunhofer-Gesellschaft
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ustekinumab in psoriatic arthritis (PsA) (2 arms), sponsored by Fraunhofer-Gesellschaft. Primary endpoint: Mean DAS28 at week 24. Started Sep 2016; status: completed.
02
Drugs
ustekinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2015-005777-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005777-20.